Pharma Stocks news from FiercePharma
News
Silver lining to Big Pharma's cloud?
Some people see the Big Pharma glass as half-full instead of the alternative. In an investor's-eye look at the industry, Kiplinger ticks off the usual criticisms: patent expirations, tough generics Read more...
Glaxo bonds bring whopping $9B
GlaxoSmithKline went hat in hand to the bond markets and came back with a record $9 billion. Intending to sell $6 billion in corporate bonds, GSK added $3 billion more as investors hungry for Read more...
Under pharma earnings, basic problems
You've heard of see-through buildings. How about see-through pharma earnings? Though drug makers have been reporting increases to their bottom lines, investors are looking past the foreign-currency Read more...
Woe is Pfizer, analysts say
Pfizer shares hit a 10-year low yesterday. And who can blame investors who sold, considering the Eeyore tone Wall Street analysts took after the drugmaker announced its Read more...
Falling dollar, falling drugmaker prices
Is the U.S. drug industry bargain-basement land right now? Analysts say that the low, low dollar means low, low prices for pharma companies. Rivals in Asia and the Eurozone could snap up drug Read more...
Teva to expand in Spain with Bentley buy
Teva Pharmaceutical is on an expansion quest. Today it's agreed to buy Bentley Read more...
Worst Pharma Stocks of 2007
When we set out last week to identify the best-performing pharma stocks of 2007, we could resist scrolling to the bottom of the spreadsheet to Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight